IBDEI0SB ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28457,1,3,0)
 ;;=3^Chronic leukemia of unspecified cell type, in remission
 ;;^UTILITY(U,$J,358.3,28457,1,4,0)
 ;;=4^C95.11
 ;;^UTILITY(U,$J,358.3,28457,2)
 ;;=^5001854
 ;;^UTILITY(U,$J,358.3,28458,0)
 ;;=C95.12^^105^1381^27
 ;;^UTILITY(U,$J,358.3,28458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28458,1,3,0)
 ;;=3^Chronic leukemia of unspecified cell type, in relapse
 ;;^UTILITY(U,$J,358.3,28458,1,4,0)
 ;;=4^C95.12
 ;;^UTILITY(U,$J,358.3,28458,2)
 ;;=^5001855
 ;;^UTILITY(U,$J,358.3,28459,0)
 ;;=D46.9^^105^1381^51
 ;;^UTILITY(U,$J,358.3,28459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28459,1,3,0)
 ;;=3^Myelodysplastic syndrome, unspecified
 ;;^UTILITY(U,$J,358.3,28459,1,4,0)
 ;;=4^D46.9
 ;;^UTILITY(U,$J,358.3,28459,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,28460,0)
 ;;=C95.90^^105^1381^39
 ;;^UTILITY(U,$J,358.3,28460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28460,1,3,0)
 ;;=3^Leukemia, unspecified not having achieved remission
 ;;^UTILITY(U,$J,358.3,28460,1,4,0)
 ;;=4^C95.90
 ;;^UTILITY(U,$J,358.3,28460,2)
 ;;=^5001856
 ;;^UTILITY(U,$J,358.3,28461,0)
 ;;=C95.91^^105^1381^41
 ;;^UTILITY(U,$J,358.3,28461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28461,1,3,0)
 ;;=3^Leukemia, unspecified, in remission
 ;;^UTILITY(U,$J,358.3,28461,1,4,0)
 ;;=4^C95.91
 ;;^UTILITY(U,$J,358.3,28461,2)
 ;;=^5001857
 ;;^UTILITY(U,$J,358.3,28462,0)
 ;;=C95.92^^105^1381^40
 ;;^UTILITY(U,$J,358.3,28462,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28462,1,3,0)
 ;;=3^Leukemia, unspecified, in relapse
 ;;^UTILITY(U,$J,358.3,28462,1,4,0)
 ;;=4^C95.92
 ;;^UTILITY(U,$J,358.3,28462,2)
 ;;=^5001858
 ;;^UTILITY(U,$J,358.3,28463,0)
 ;;=D72.9^^105^1381^35
 ;;^UTILITY(U,$J,358.3,28463,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28463,1,3,0)
 ;;=3^Disorder of white blood cells, unspecified
 ;;^UTILITY(U,$J,358.3,28463,1,4,0)
 ;;=4^D72.9
 ;;^UTILITY(U,$J,358.3,28463,2)
 ;;=^5002381
 ;;^UTILITY(U,$J,358.3,28464,0)
 ;;=D75.1^^105^1381^59
 ;;^UTILITY(U,$J,358.3,28464,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28464,1,3,0)
 ;;=3^Secondary polycythemia
 ;;^UTILITY(U,$J,358.3,28464,1,4,0)
 ;;=4^D75.1
 ;;^UTILITY(U,$J,358.3,28464,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,28465,0)
 ;;=D75.9^^105^1381^34
 ;;^UTILITY(U,$J,358.3,28465,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28465,1,3,0)
 ;;=3^Disease of blood and blood-forming organs, unspecified
 ;;^UTILITY(U,$J,358.3,28465,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,28465,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,28466,0)
 ;;=C7A.010^^105^1381^42
 ;;^UTILITY(U,$J,358.3,28466,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28466,1,3,0)
 ;;=3^Malignant carcinoid tumor of the duodenum
 ;;^UTILITY(U,$J,358.3,28466,1,4,0)
 ;;=4^C7A.010
 ;;^UTILITY(U,$J,358.3,28466,2)
 ;;=^5001359
 ;;^UTILITY(U,$J,358.3,28467,0)
 ;;=C7A.011^^105^1381^44
 ;;^UTILITY(U,$J,358.3,28467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28467,1,3,0)
 ;;=3^Malignant carcinoid tumor of the jejunum
 ;;^UTILITY(U,$J,358.3,28467,1,4,0)
 ;;=4^C7A.011
 ;;^UTILITY(U,$J,358.3,28467,2)
 ;;=^5001360
 ;;^UTILITY(U,$J,358.3,28468,0)
 ;;=C7A.012^^105^1381^43
 ;;^UTILITY(U,$J,358.3,28468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28468,1,3,0)
 ;;=3^Malignant carcinoid tumor of the ileum
 ;;^UTILITY(U,$J,358.3,28468,1,4,0)
 ;;=4^C7A.012
 ;;^UTILITY(U,$J,358.3,28468,2)
 ;;=^5001361
 ;;^UTILITY(U,$J,358.3,28469,0)
 ;;=C93.30^^105^1381^38
 ;;^UTILITY(U,$J,358.3,28469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28469,1,3,0)
 ;;=3^Juvenile myelomonocytic leukemia,no remission
 ;;^UTILITY(U,$J,358.3,28469,1,4,0)
 ;;=4^C93.30
 ;;^UTILITY(U,$J,358.3,28469,2)
 ;;=^5001825
 ;;^UTILITY(U,$J,358.3,28470,0)
 ;;=C93.31^^105^1381^37
 ;;^UTILITY(U,$J,358.3,28470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28470,1,3,0)
 ;;=3^Juvenile myelomonocytic leukemia,in remission
 ;;^UTILITY(U,$J,358.3,28470,1,4,0)
 ;;=4^C93.31
 ;;^UTILITY(U,$J,358.3,28470,2)
 ;;=^5001826
 ;;^UTILITY(U,$J,358.3,28471,0)
 ;;=C93.32^^105^1381^36
 ;;^UTILITY(U,$J,358.3,28471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28471,1,3,0)
 ;;=3^Juvenile myelomonocytic leukemia,in relapse
 ;;^UTILITY(U,$J,358.3,28471,1,4,0)
 ;;=4^C93.32
 ;;^UTILITY(U,$J,358.3,28471,2)
 ;;=^5001827
 ;;^UTILITY(U,$J,358.3,28472,0)
 ;;=D48.0^^105^1382^5
 ;;^UTILITY(U,$J,358.3,28472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28472,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of bone/artic cartl
 ;;^UTILITY(U,$J,358.3,28472,1,4,0)
 ;;=4^D48.0
 ;;^UTILITY(U,$J,358.3,28472,2)
 ;;=^81953
 ;;^UTILITY(U,$J,358.3,28473,0)
 ;;=D48.1^^105^1382^6
 ;;^UTILITY(U,$J,358.3,28473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28473,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of connctv/soft tiss
 ;;^UTILITY(U,$J,358.3,28473,1,4,0)
 ;;=4^D48.1
 ;;^UTILITY(U,$J,358.3,28473,2)
 ;;=^267776
 ;;^UTILITY(U,$J,358.3,28474,0)
 ;;=D48.5^^105^1382^10
 ;;^UTILITY(U,$J,358.3,28474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28474,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of skin
 ;;^UTILITY(U,$J,358.3,28474,1,4,0)
 ;;=4^D48.5
 ;;^UTILITY(U,$J,358.3,28474,2)
 ;;=^267777
 ;;^UTILITY(U,$J,358.3,28475,0)
 ;;=D48.61^^105^1382^9
 ;;^UTILITY(U,$J,358.3,28475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28475,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of right breast
 ;;^UTILITY(U,$J,358.3,28475,1,4,0)
 ;;=4^D48.61
 ;;^UTILITY(U,$J,358.3,28475,2)
 ;;=^5002267
 ;;^UTILITY(U,$J,358.3,28476,0)
 ;;=D48.62^^105^1382^7
 ;;^UTILITY(U,$J,358.3,28476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28476,1,3,0)
 ;;=3^Neoplasm of uncertain behavior of left breast
 ;;^UTILITY(U,$J,358.3,28476,1,4,0)
 ;;=4^D48.62
 ;;^UTILITY(U,$J,358.3,28476,2)
 ;;=^5002268
 ;;^UTILITY(U,$J,358.3,28477,0)
 ;;=D47.0^^105^1382^2
 ;;^UTILITY(U,$J,358.3,28477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28477,1,3,0)
 ;;=3^Histiocytic and mast cell tumors of uncertain behavior
 ;;^UTILITY(U,$J,358.3,28477,1,4,0)
 ;;=4^D47.0
 ;;^UTILITY(U,$J,358.3,28477,2)
 ;;=^5002255
 ;;^UTILITY(U,$J,358.3,28478,0)
 ;;=D46.0^^105^1382^18
 ;;^UTILITY(U,$J,358.3,28478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28478,1,3,0)
 ;;=3^Refractory anemia without ring sideroblasts, so stated
 ;;^UTILITY(U,$J,358.3,28478,1,4,0)
 ;;=4^D46.0
 ;;^UTILITY(U,$J,358.3,28478,2)
 ;;=^5002245
 ;;^UTILITY(U,$J,358.3,28479,0)
 ;;=D46.1^^105^1382^17
 ;;^UTILITY(U,$J,358.3,28479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28479,1,3,0)
 ;;=3^Refractory anemia with ring sideroblasts
 ;;^UTILITY(U,$J,358.3,28479,1,4,0)
 ;;=4^D46.1
 ;;^UTILITY(U,$J,358.3,28479,2)
 ;;=^5002246
 ;;^UTILITY(U,$J,358.3,28480,0)
 ;;=D46.20^^105^1382^14
 ;;^UTILITY(U,$J,358.3,28480,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28480,1,3,0)
 ;;=3^Refractory anemia with excess of blasts, unspecified
 ;;^UTILITY(U,$J,358.3,28480,1,4,0)
 ;;=4^D46.20
 ;;^UTILITY(U,$J,358.3,28480,2)
 ;;=^5002247
 ;;^UTILITY(U,$J,358.3,28481,0)
 ;;=D46.21^^105^1382^15
 ;;^UTILITY(U,$J,358.3,28481,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28481,1,3,0)
 ;;=3^Refractory anemia with excess of blasts 1
 ;;^UTILITY(U,$J,358.3,28481,1,4,0)
 ;;=4^D46.21
 ;;^UTILITY(U,$J,358.3,28481,2)
 ;;=^5002248
 ;;^UTILITY(U,$J,358.3,28482,0)
 ;;=D46.A^^105^1382^19
 ;;^UTILITY(U,$J,358.3,28482,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28482,1,3,0)
 ;;=3^Refractory cytopenia with multilineage dysplasia
 ;;^UTILITY(U,$J,358.3,28482,1,4,0)
 ;;=4^D46.A
 ;;^UTILITY(U,$J,358.3,28482,2)
 ;;=^5002251
 ;;^UTILITY(U,$J,358.3,28483,0)
 ;;=D46.B^^105^1382^13
 ;;^UTILITY(U,$J,358.3,28483,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28483,1,3,0)
 ;;=3^Refract cytopenia w multilin dysplasia and ring sideroblasts
 ;;^UTILITY(U,$J,358.3,28483,1,4,0)
 ;;=4^D46.B
 ;;^UTILITY(U,$J,358.3,28483,2)
 ;;=^5002252
 ;;^UTILITY(U,$J,358.3,28484,0)
 ;;=D46.22^^105^1382^16
